The stock of Catalyst Biosciences Inc. (NASDAQ:CBIO) decreased by $0.0 on Monday to $0.59, up 0.22 percent. The last five days have seen an average of 971,075 shares of common stock traded. 5 times new highs were reached in the current year, with a gain of $0.0426. The average number of shares traded over the last 20 days was 601,519, while the average volume over the last 50 days totaled 824,028.
CBIO stock appreciated 58.10% since last month. On 08/11/23, the company’s shares reached a one-month low of $0.3200. The stock touched a high of $0.74 on 08/23/23, after rallying from a low of $0.19 in 52 weeks. The price of CBIO stock has risen by 81.51% or $0.0426 this year, reaching a new high 5 times. Still, the stock price is down -19.90% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
Company paid $0.24 per share in dividends, a decrease of -83.22% from $1.43 last year.
Financial Health
For the three months ended June 29, Catalyst Biosciences Inc.’s quick ratio was 2.70, while its current ratio was 2.70, indicating its ability to pay off its debt. Based on annual data, it had gross profit of $4000.0 and revenue of $0.79 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. CBIO’s return on assets (ROA) during the last 12 months has been -209.90%. There was a 40.50% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 408.30%.
Earnings Surprise
According to Catalyst Biosciences Inc.’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. It was predicted that Catalyst Biosciences Inc.’s quarterly earnings would be -$0.07, but it ended up being -$0.07. EBITDA was -$2.54 million for the quarter. Equity owned by shareholders amounts to $37.98 million.
Technical Picture
Here’s a quick look at Catalyst Biosciences Inc.’s (CBIO) price momentum from a technical perspective. As of 25 August, the RSI 9-day stood at 62.45%, suggesting the stock is Neutral, with a 174.67% historical volatility rate.
The stochastic %K and %D were 57.26% and 64.34% respectively, while the average true range (ATR) was 0.0797. Based on the 14-day stochastic reading of 59.55%, the RSI (14) reading is 63.21%. On the 9-day MACD Oscillator, the stock is at 0.0146, and the 14-day reading is at 0.0856.
Analyst Ratings
Analysts have assigned Catalyst Biosciences Inc. (CBIO) an Hold rating. CBIO is a stock that is recommended for selling by 0 brokerage firms, while 1 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 0 others recommend it as a buy.
What is CBIO’s price target for the next 12 months?
The current consensus forecast for the stock is between $3.00 and $3.00, with a median target price of $3.00. In analyzing these forecasts, the average price target given by analysts for Catalyst Biosciences Inc. (CBIO) is $3.00.
